Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
KalVista Pharmaceuticals
About
KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME).
- Cambridge,Massachusetts,United States
- 51 - 100
- http://www.kalvista.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $58M
- Industries
- Biotechnology,Diabetes,Health Care
- Founded date
- Jan 1, 2011
- Number Of Employee
- 51 - 100
- Operating Status
- Active
- Stock Symbol
- nasdaq:KALV
- Legal Name
- KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries. KalVista has an advanced pre-clinical product pipeline resulting from over 20 years of leading pharmaceutical discovery in the field of serine protease inhibitors and is targeting both intravitreal injection and oral administration. Although VEGF inhibitors clearly can benefit DME, a significant number of patients do not respond fully to these agents and have limited treatment options. Plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 27, 2022 | Post-IPO Equity | $58M | — | — | — | Detail |
| Feb 10, 2021 | Post-IPO Equity | $193.50M | — | — | — | Detail |
| Sep 6, 2015 | IPO | $68M | — | — | — | Detail |
| Jul 22, 2015 | Series B | $33M | 5 |
RA Capital Management
|
— | Detail |
| Aug 23, 2011 | Series A | £8M | 2 |
Novo Holdings
SV Health Investors
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
RA Capital Management
|
Yes | Series B |
Longwood Fund
|
— | Series B |
|
Novo Holdings
|
— | Series B |
|
SV Health Investors
|
— | Series B |
Venrock
|
— | Series B |
Employee Profiles
Acquisition
KalVista Pharmaceuticals has acquired 1 organizations. Their most recent acquisition was Carbylan Therapeutics on Jun 15, 2016. They acquired Carbylan Therapeutics for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Jun 15, 2016
Carbylan Therapeutics
|
Health Care | acquisition | — | Detail |
